Ivabradina Pensa

Ivabradine, the active ingredient in Ivabradina Pensa, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution, following EU Good Manufacturing Practice to ensure batch consistency and safety.

Ivabradina Pensa acts on the cardiac If current to lower heart rate, providing therapeutic benefit in several cardiovascular conditions. - Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: decreases heart rate, contributing to better ventricular remodeling and reduced hospitalization risk. - Symptomatic tachycardia: lowers elevated heart rate when other rate‑controlling agents are unsuitable.

Ivabradina Pensa may be associated with several adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below prescribed range. - Headache. - Dizziness.

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical intervention. - Atrial fibrillation or other serious arrhythmias. - Persistent visual impairment or retinal toxicity.

When prescribing Ivabradina Pensa, clinicians should observe the following precautions to ensure patient safety. - Cardiovascular assessment: evaluate baseline heart rate and rhythm before initiation. - Monitor heart rate: check regularly, especially after dose changes. - Contraindication in severe hepatic impairment: avoid or use with caution. - Caution with sick sinus syndrome or atrioventricular block: may exacerbate bradyarrhythmias. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors that can increase plasma levels. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Ivabradina Pensa can interact with other medicines, altering its plasma concentration or additive cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine levels and increase bradycardia risk. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil): can cause excessive heart‑rate reduction. - Concomitant use with other If channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): can lower ivabradine exposure, reducing efficacy. - Antihypertensive agents: monitor blood pressure and heart rate for additive effects.